|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 反应停治疗多发性骨髓瘤的现况与展望显示文摘1 引言
20世纪50年代,反应停作为一种镇静剂进入欧洲市场,且发现其对减轻孕妇晨吐症状特别有效.众所周知,在认识了它的致畸作用,尤其是引起短肢畸形后,于1961年被停止使用. | Cavenagh JD Oakervee H 徐泽锋 肖志坚 郝玉书 | 2003 | 国外医学(输血及血液学分册)2003，26，1： | 11 |
| 2 | Hepatitis-associated aplastic anaemia treated successfully with antilymphocyte globulin 显示文摘 | Bhattacharyya M Oakervee H Dalley C | 2005 | Clin Lab Haematol2005，27，5： | 1 |
| 3 | Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma:impact on stem cell harvesting and engraftment显示文摘 | Oakervee H Popat R Cavenagh JD | | 0，，： | 1 |
| 4 | PAD combination therapy(ps-341/bortezomib, doxorubicin and dexamethasone)for previously untreated patients with multiple myeloma显示文摘 | OAKERVEE HE POPAT R CURRY N | 2005 | Br J Haematol2005，129，6： | 1 |
| 5 | Thlidomide in multiple myeloma: current status and future prospects显示文摘 | Cavenagh JD Oakervee H | 2003 | Br J Haematol2003，120，： | 1 |
| 6 | PAD combination therapy(PS-341/bortezomib, doxorubicin and dexamethasone) for previouslyuntreated patients with multiple myeloma 显示文摘 | Oakervee HE Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
| 7 | PAD combination therapy ( PS-341/bortezomib, doxorubicin and dexamethasone ) for previously untreated patients with multiple myeloma 显示文摘 | Oakervee H Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
| 8 | A study of the safety and efficacy of oral melphalan,prednisolone and thalidomide(MPT)in the treatment of multiple myeloma:A UK Myeloma Forum Pilot Study显示文摘 | Oakervee H Baugh H Boots M | 2002 | Br J Haematol2002，117，1： | 1 |
| 9 | A study of the safety and efficacy of thalidomide combined with vincristine,adriamycin and dexamethasone(T-VAD)in the treatment of younger patients with multiple myeloma:A UK Myeloma Forum Pilot Study显示文摘 | Oakervee H Brownell A Cerri P | 2002 | Br J Haematol2002，117，1： | 1 |
| 10 | PAD combination therapy (PS-341/ bortezomib,doxorubicin and dexamethasone)for previously untreated patients with multiple myeloma显示文摘 | Oakervee HE Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
| 11 | PAD combination therapy (PS-341/bortezomib,doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma显示文摘 | Oakervee HE Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
| 12 | Hepatitis-associated aplastic anemia treated successfully with antilymphocyte globulin 显示文摘 | Bhattacharyya M Oakervee H Dalley C | 2005 | Clin Lab Haematol2005，27，5： | 1 |
| 13 | Bortezomib,doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma:updated results after long-term follow-up显示文摘 | Popat R Oakervee HE Hallam S | 2008 | Br J Haematol2008，141，4： | 1 |
| 14 | Bortezomib, low-doseintravenous melphalan, and dexamethasone for patients with relapsedmultiple myeloma显示文摘 | Popat R Oakervee H Williams C | 2009 | Br J Haematol2009，144，6： | 1 |
| 15 | PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone)for previously untreated patients with multiple rnyelorna显示文摘 | Oakervee HE Popat R Curry N et aI | 2005 | Br J Haernato)2005，129，6： | 1 |
| 16 | (PS-341/boftezomib, doxorubicin and dexamethasone) for previously untreated pa- tients with multiple myeloma显示文摘 | OAKERVEE H E THERAPY P C | 2005 | Br J Haematol2005，129，6： | 1 |
| 17 | Thalidomide in multiple myeloma : Current status and future prospects显示文摘 | Cavenagh JD Oakervee H | 2003 | Br J Haematol2003，120，1： | 1 |
| 18 | PAD CombinationTherapy (PS -341/Bortezomib,Doxorubicin and Dexametha-sone) for Previously Untreated Patients with Multipe Myeloma显示文摘 | Oakervee H E Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
| 19 | PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma 显示文摘 | Oakervee HE Popat R | 2005 | Br J Haematol2005，129，6： | 1 |
| 20 | PAD combination therapy (PS-341/bortezomib,doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma显示文摘 | Oakervee HE Popat R Curry N | 2005 | Br J Haematol2005，129，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员